<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393467</url>
  </required_header>
  <id_info>
    <org_study_id>STIMALS</org_study_id>
    <nct_id>NCT04393467</nct_id>
  </id_info>
  <brief_title>Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS).</brief_title>
  <official_title>Efficacy of Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate safety and efficacy of tSMS in ALS patients and to obtain
      preliminary data about the effects of tSMS on cortical excitability.

      To this purpose, 40 ALS patients will be recruited and randomized to real or sham tSMS. After
      3 months follow-up, they will undergo tSMS, daily for 120 min, at home, for 6 consecutive
      months.

      Clinical status will be tested before, during and after the stimulation period. Moreover,
      cortical excitability will be tested by transcranial magnetic stimulation (TMS) before and
      after the stimulation period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease progression</measure>
    <time_frame>9 months</time_frame>
    <description>Comparison between the ALSFRS-R (Revised Amyotrophic Lateral Sclerosis Functional Rating Scale) decline over the period of three months before the treatment and the period of six months during the treatment. The ALSFRS-R is 12-items scale ranking from 0 (worse) to 48 (better) points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of adverse events during the stimulation period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>6 months</time_frame>
    <description>Number of stimulation sessions actually completed by each patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on resting motor threshold (RMT) and active motor threshold (AMT)</measure>
    <time_frame>6 months</time_frame>
    <description>Change in TMS-derived cortical excitability parameters (RMT and AMT) before and after stimulation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on motor evoked potentials (MEP) size</measure>
    <time_frame>6 months</time_frame>
    <description>Change in TMS-derived cortical excitability parameters (MEP size) before and after stimulation period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>real tSMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tSMS will be delivered by a magnet applied to M1, bilaterally (120 min daily, for 6 months). Magnet will be kept in position by a plastic helmet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham tSMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>A non-magnetic steel cylinder, with same size, weight and appearance of the magnet, will be used for sham stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tSMS</intervention_name>
    <description>tSMS delivered on bilateral motor cortex</description>
    <arm_group_label>real tSMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham tSMS</intervention_name>
    <description>sham tSMS delivered on bilateral motor cortex by a non-magnetic steel cylinder, with same size, weight and appearance of the magnet used for real tSMS</description>
    <arm_group_label>sham tSMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 75 years

          -  diagnosis of ALS according to revised El Escorial criteria and Awaji-Shima criteria

          -  disease duration &lt; 24 months

          -  ALSFRS-R &gt; 30 at the recruitment

          -  ALSFRS-R decline &gt; 1 in the 3-months period before the intervention

          -  normal respiratory functionality (FVC &gt; 80% and ALSFRS-R items 10,11,12 &gt; 4) at the
             recruitment

          -  treatment with riluzole 50 mg x 2/die

        Exclusion Criteria:

          -  inclusion in other clinical trials

          -  presence of tracheotomy or/and PEG (percutaneous endoscopic gastrostomy)

          -  contraindications to magnetic fields exposure

          -  pregnancy or breast-feeding

          -  history of epilepsy or seizures

          -  assumption of drugs acting on central nervous system, except for antidepressive drugs
             and benzodiazepines.

          -  cognitive impairment

          -  lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Silani, MD</last_name>
      <phone>+39 02619111</phone>
      <email>vincenzo.silani@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurology Unit, Campus Biomedico University</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Di Lazzaro, MD</last_name>
      <phone>+39 06 22541 1320</phone>
      <email>v.dilazzaro@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Fioravante Capone, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marilisa Boscarino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 16, 2020</last_update_submitted>
  <last_update_submitted_qc>May 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Campus Bio-Medico University</investigator_affiliation>
    <investigator_full_name>Di Lazzaro Vincenzo</investigator_full_name>
    <investigator_title>Full Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>ALS</keyword>
  <keyword>transcranial magnetic stimulation</keyword>
  <keyword>static magnetic field</keyword>
  <keyword>tSMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

